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Abstract
Atypical teratoid/rhabdoid tumor is predominantly a childhood tu-
mor and has only been rarely reported in adults; therefore, treat-
ment regimens are often extrapolated from the pediatric experience. 
Typically, children are treated with craniospinal radiation therapy 
which is often followed by systemic chemotherapy. Employing pe-
diatric regimens to treat this tumor in adult patients poses a particu-
lar risk for myelosuppression, as the prescribed doses in pediatric 
protocols exceed those tolerated by adults, and conventional cra-
niospinal radiation can be associated with prolonged myelotoxicity 
and a depletion of the bone marrow reserve in vertebrae of adults. 
Here we present a case of a woman with a pineal region atypical 
teratoid/rhabdoid tumor, an unusual adult cancer presenting in an 
atypical location. This is followed by a review of the disease in 
adult patients with an emphasis on treatment and suggestions to 
minimize myelotoxicity.
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Case Report
A 33-year-old right-handed woman developed the sensation 
of fullness in her head followed months later by blurred vi-
sion that progressed to double vision. Brain MRI identiﬁ  ed 
a large pineal mass and hydrocephalus (Fig. 1). A subtotal 
resection of the mass with concurrent placement of a ventric-
uloperitoneal shunt was performed at an outside institution 
(Fig. 2). Pathology suggested an epithelioid neoplasm, but a 
deﬁ  nitive diagnosis could not be made. Three weeks later, 
the tumor had regrown to its original size and a repeat supra-
cerebellar infratentorial craniotomy was performed at MD 
Anderson Cancer Center with a near complete resection of 
the pineal mass (Fig. 3). Immunohistochemistry was positive 
for epithelial membrane antigen and smooth muscle actin. 
An antibody against the hSNF5/INI1 protein was negative in 
tumor cell nuclei. These ﬁ  ndings conﬁ  rmed the diagnosis of 
atypical teratoid/rhabdoid tumor (AT/RT), WHO grade IV. 
Cerebrospinal ﬂ  uid and spinal MRIs were negative for tumor 
dissemination.
Peripheral blood stem collection was performed prior to 
the initiation of chemotherapy. The patient underwent cra-
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Figure 1. Pre-operative MRI.
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niospinal radiation therapy (CSRT) and post-radiation MRI 
showed a modest decrease in the size of the residual tumor. 
Chemotherapy with Ifosphamide, Etoposide and Carboplatin 
(ICE) was given in 3-week cycles. After two cycles, brain 
MRI showed a partial tumor response. After her eighth cycle 
there was evidence of tumor progression with recurrence in 
the thalamus as well as along the occipital horn of the lateral 
ventricle. The treatment regimen was changed to doxoru-
bicin, vincristine and temozolomide. The patient continues 
on this treatment regimen, and remains clinically and radio-
graphically stable 18 months after the initial diagnosis.
Review of the Literature
The history of AT/RT
Beckwith and Palmer, in 1978, ﬁ  rst coined the term ‘rhab-
doid tumor’ to describe a histological variant of Wilm’s tu-
mor found primarily in infants that was associated with an 
extremely poor prognosis [1]. The name was derived from 
its similarity in gross tumor appearance to a rhabdomyosar-
coma; however, the cells differed from the expected mor-
phological and immunohistochemical features of muscle [2]. 
A tumor composed of rhabdoid cells in the central nervous 
system (CNS), was ﬁ  rst reported in 1985 [3]. The name 
‘atypical teratoid/rhabdoid tumor’ (AT/RT) exempliﬁ  es the 
tumor’s disparate mixtures of rhabdoid, primitive neuroepi-
thelial, mesenchymal and epithelial components [4]. AT/RT 
is much more frequently seen in infants and young children 
than older children and is rare in adults. AT/RT has an over-
all incidence of 1 - 2% of all brain tumors in children [4, 
5]. They are estimated to account for over 10% of CNS tu-
mors in infants, with a male preponderance up to the age of 
3 which then seems to disappear [6, 7]. There exists a rhab-
doid tumor predisposition syndrome which can be inherited 
in an autosomal dominant fashion, but most commonly oc-
curs sporadically. The genetic form of AT/RT results from a 
germline loss of function mutations in INI1, also known as 
SMARCB1, a tumor suppressor gene at 22q11.23 [8]. This 
syndrome commonly manifests in tumors of the kidneys, 
brain and soft tissues. There have been just over 30 adult 
cases reported in the literature to date [9-31] (summarized 
in Table 1). Clinical presentation varies with tumor location 
in adults where a variety of primary locations have been re-
ported.
No data exists to support imaging characteristics that 
differentiate AT/RTs from other primitive neuroectodermal 
tumors [32]. Report from the AT/RT workshop in 2002 noted 
that half of all AT/RTs are in the posterior fossa, although the 
tumor has been noted throughout the nervous system and in 
extramedullary sites. Tumors can be extraaxial and invade 
adjacent structures such as the meninges as well [32]. In 
adults, these are primarily found in the cerebral hemispheres 
[33] and are rare in the cerebellum and spinal cord [16, 17, 
19, 21, 25]. Similar to our case, two other adult AT/RTs have 
been found in the pineal region [23, 34].
Computed tomography (CT) usually shows a hyperdense 
mass that intensely enhances after administration of intrave-
nous contrast. On T1-weighted magnetic resonance imaging 
(MRI) the mass is commonly isointense with hyperintense 
areas that result from intratumoral bleeding. The T2 imag-
ing is more heterogenous with hypointense to hyperintense 
areas indicating a mixture of necrosis, hemorrhage, cystic 
changes, and calciﬁ  cations [32, 35]. Peritumoral edema was 
variable in the meta-analysis of 133 patients done by Oka 
[36]. MR spectroscopy shows a marked elevation of choline 
and low or absent N-acetylaspartate (NAA) and creatinine, 
as would be expected. In a review of thirteen patients ages 
4 months to 15 years with AT/RT, all tumors except one en-
hanced with contrast on MRI [35].
AT/RTs consist of a combination of rhabdoid, primitive 
Figure 2. MRI after ﬁ  rst resection. Figure 3. MRI after second resection.
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Table 1. Adult Patients With AT/RT in the CNS
Author (year) (ref)
Age 
(yr)/
Sex
Tumor 
Location
Immunostains LMD
Diagnosis 
Conﬁ  rmed
INI1 
Analysis
Primary 
Treatment
Secondary 
Treatment
TTP 
(mos)
OS 
(mos)
Balaton (1987) [27] 59M Paravertebral CK Vim Y IHC N None n/a n/a 0.5
Horn (1992) [9] 21M L temporal EMA Vim N IHC N STR STR CT 48 72
Cossu (1993) [26] 18M L frontal  CK EMA Vim N IHC N GTR CT STR 5 18
Fisher (1996) [10] 32M L caudate
cGFAP S100 
Vim
Y IHC N None n/a n/a 1
Ashraf (1997) [11] 34M L parietal Vim N IHC N STR RT STR 2 6
Byram (1999) [12] 35M L temporal NA N NA NA GTR RT GTR 36 60
Sugita (1999) [34] 27M Pineal region chrA EMA NSE 
S100 Vim
N IHC N STR CRT 
ACNU
STR 18 24
Kuge (2000) [13] 32F Suprasellar
CK EMA SMA 
Vim
Y, r IHC N STR
CSRT
CDDP, 
VP16, IFN
IT mtx
18 +
Arrazola (2000) [14] 20M L parietal
CK EMA S100 
Vim
N IHC N GTR GTR CSRT 3 84
Lutterbach (2001) [15] 30F Cerebellum CK S100 Vim N IHC N
GTR
RT SRS Tmz 6 11
Bruch (2001) [16] 21F Spinal cord CK EMA Vim N IHC, 22qdel N NA NA NA 6
Bruch (2001) [16] 34F Parietal CK EMA Vim N IHC, 22qdel N NA NA NA 6
Pimentel (2003) [17] 31F R parietal
EMA GFAP 
S100 Vim
alpha1ac/at
Y IHC N STR
CSRT
ICE
16
Kachhara (2003) [19] 35M Thalamus Vim N IHC N
STR
RT
-2 N A
Kawaguchi (2004) [18] 22M L cerebellum
CK EMA NSE 
SMA Vim
Y IHC N
STR
CSRT
ICE IT 
mtx
- n/a 24+
Raisanen (2005) [20] 45M R cerebellum
CK EMA S100 
SMA Vim
N IHC Y Sx CT RT NA NA 15+
Raisanen (2005) [20] 20F Sella 
CK EMA SMA 
Vim
N IHC Y Sx R CT CT NA 28+
Raisanen (2005) [20] 31F Sella CK EMA Vim N IHC Y Sx RT NA NA 9
Erickson (2005) [21] 20F R occiput
EMA GFAP 
SMA Vim
N IHC Y GTR RT NA NA
Chen (2006) [28] 19M Post fossa NA NA NA NA GTR CSRT 7 56.5
Ingold (2006) [22] 45F Pineal
CK EMA SMA 
Vim
Y, r IHC Y GTR CRT GTR 6 7
Rezanko (2006) [23] 27M R frontal EMA S100 Vim Y, r IHC N GTR RT - 4 4
Chacko (2007) [29] 23M R frontal EMA SMA Vim N IHC Y
STR
RT
GTR 1 2
Zarovnaya (2007) [24] 43F Spinal cord EMA Y, r IHC Y STR RT
CSRT
Tmz IFN
23 0
Makuria (2008) [30] 23M L temporal
CK EMA NF 
SMA
Syn Vim
N IHC Y Sx RT CT - n/a 30+
Makuria (2008) [30] 25F R frontal
NF SMA Syn 
Vim
N IHC Y GTR
GTRx5
GKS RT
24 204+
Makuria (2008) [30] 42M
R frontal-
parietal
CK EMA Vim N IHC Y
STR
RT
CT
- - 18+
Makuria (2008) [30] 37M
R frontal-
parietal
Vim N IHC Y NA NA NA
Arita (2008) [31] 56F
Sella/cav 
sinus
EMA NF Vim Y, r IHC Y STR SRS CSRT 12 23
Samaras (2009) [25] 18M
R frontal-
temporal
EMA GFAP 
SMA Vim
N IHC Y
GTR
RT
-- 4
Our patient 33F Pineal region EMA SMA N IHC Y
GTR 
CSRT
ICE
Tmz + Vcr 8 18+
LMD: leptomeningeal disease; Y: yes; N: no; Y, r: yes at recurrence; IHC: Immunohistochemistry; NA: not avail-
able; STR: subtotal resection; GTR: gross total resection; CT: chemotherapy; CRT: chemoradiation; RT: radiation 
therapy; CSRT: craniospinal radiation therapy; IT: intrathecal; Sx: surgery (extent unknown); n/a: not applicable; CK: 
cytokeratin; Vim: vimentin; EMA: epithelial membrane antigen; cGFAP: cytoplasmic glial ﬁ  brillary acid protein; SMA: 
smooth muscle actin; chrA: chromogranin A; NSE: neuron-speciﬁ  c enolase; alpha1ac/at: alpha-1 antichymotrypsin/
antitrypsin; NF: neuroﬁ  bromin; ACNU: Nimustine; ICE: ifosphamide, carboplatin, etoposide; mtx: methotrexate; SRS: 
stereotactic radiosurgery; CDDP: Cisplatin; VP16: etoposide; IFN: interferon-gamma; Tmz: temozolomide; GKS: 
gamma-knife surgery; Vcr: vincristine.
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neuroepithelial, mesencymal and epithelial cells. Approxi-
mately one-third contain epithelial or mesenchymal cells, 
and only 10% are comprised purely of rhabdoid cells [32]. 
This heterogeneity makes the discrimination between AT/RT 
and the other tumors of embryonal tissue, namely medul-
loblastoma and primitive neuroectodermal tumor (PNET), 
difﬁ  cult using histologic criteria [37, 38]. Thus far, the his-
togenesis of this tumor has remained elusive [10, 32, 39]. 
Proliferative activity is high, and Ki-67/MIB-1 labelling in-
dices averaged 63.9% in a series of pediatric patients [40], 
and have ranged from less than 20% to 80% [9, 12, 16, 34].
Immunohistochemistry (IHC) is positive for rhabdoid 
cell markers including epithelial membrane antigen (EMA), 
vimentin, and smooth-muscle actin (SMA) in the majority of 
tumors and markers for germ-cell tumors such as alpha-fe-
toprotein and placental alkaline phosphatase are consistently 
negative [4, 32]. The tumors may also express glial ﬁ  brillary 
acidic protein, keratin, synaptophysin, and neuroﬁ  lament 
protein [32]. IHC staining for the INI1 protein, a component 
of a SWI/SNF ATP-dependent chromatin-remodeling com-
plex has been shown to be highly sensitive and speciﬁ  c for 
AT/RTs [41-43]. Versteege suggested that any loss-of-func-
tion mutations of INI1 contribute to oncogenesis after noting 
bi-allelic alterations of INI1 (i.e., any truncating mutation 
of one allele caused loss of the other allele). Monosomy 22 
or deletions of chromosome band 22q11 are found in most 
AT/RTs, however, alterations of chromosome 22 are shared 
in other CNS tumors as well. PNETs may have deletions of 
chromosome 22 but can sometimes be differentiated from 
AT/RTs by the presence of chromosome 17 abnormalities [4, 
42, 44].
Prognosis
Tekautz and colleagues reported the outcomes from a se-
ries of 37 pediatric patients [7]. Event-free survival (EFS) 
and overall survival (OS) at two years for children aged 
three years or older was 78% and 89% vs 11% and 17 % 
for younger children. Oka performed a meta-analysis of 133 
patients and found that 98 (74%) patients had succumbed to 
their disease within 24 months of diagnosis, with a mean OS 
of 8.5 months. Seventy-ﬁ  ve percent of these patients were 
younger than three years of age [36]. Recently, the modiﬁ  ed 
IRS-III regimen evaluated by Chi and colleagues increased 
two-year survival to 70% ± 10% compared to historic me-
dian survival of only 6 - 11 months [32, 39, 45]. Of the 31 
adult patients whose survival data were reported in the lit-
erature, the median survival was 15 - 18 months, although 
it ranged widely from two weeks to over 17 years (Table 1).
Treatment
The impact of the extent of surgical resection on outcome 
has not been fully studied. Packer reported from the pediat-
ric AT/RT registry an OS of 8.5 months that lengthened to 13 
months in patients who had gross total resection (GTR) of 
their tumors. In this report, a personal communication with J. 
Hilden M.D. is cited that of the eight patients in the registry 
with an OS of greater than 18 months, six of those had un-
dergone a GTR [32]. Hilden’s report favors more aggressive 
resection as well with an OS of 20 months vs 15.25 months 
[46].
Treatment paradigms for adult patients have been ex-
tracted from the pediatric literature. Chemotherapeutic 
regimens used in the pediatric population vary, but regi-
mens commonly utilize vincristine with an alkylating and 
a platinum agent. Table 2 highlights several regimens and 
outcomes in pediatric patients.
Excluding our patient, there have been 31 adult cases 
reported in the (English) literature. There is no information 
available regarding treatment given to three of these patients, 
and no survival information was provided for three patients. 
Of the 28 adult patients in whom treatment was reported, 
14 (50%) received chemotherapy, either concurrent with or 
after radiation therapy. Temozolomide and ICE were com-
monly used. Survival in patients who received chemotherapy 
ranged from 6 months to 17 years, with a median survival 
of 24 months. Those who received surgery and radiation 
therapy without chemotherapy had a survival between 2 and 
7 years, with a median survival of 9 months. In a small case 
series, we cannot conﬁ  rm the superiority of one regimen or 
even a beneﬁ  t from chemotherapy. The data supports the 
importance of preserving bone marrow function so that sys-
temic chemotherapy remains a viable option.
Much of the data regarding treatment has focused on 
chemotherapy, since the majority of patients diagnosed with 
AT/RT are under two to three years old when RT is avoided 
if possible. Those patients over the age of three are routinely 
given RT, often in the form of CSRT as leptomeningeal dis-
ease (LMD) is often present at diagnosis and is common at 
recurrence. The AT/RT registry shows a high rate of local 
recurrence, and those who survived more than 18 months 
were more likely (75%) to have received RT [32]. Patients 
are given varying doses between 40 - 60 Gy, and stereotactic 
radiosurgery has been used for recurrent disease when resec-
tion is not feasible [47]. There are no data on the response to 
RT in adult AT/RT but of 13 patients in a case series from the 
Children’s Hospital of Philadelphia, only two patients had an 
objective response [4].
In the report on 42 pediatric cases by Hilden, 13 patients 
underwent stem cell rescue as part of their primary treatment, 
which underscores the signiﬁ  cant myelosuppression of treat-
ment regimens for AT/RT [46]. Approximately 40% of adult 
bone marrow resides in the spine [48]. In our patient, we 
were concerned about the additive myelotoxicity of CSRT 
and chemotherapy and so a stem cell harvest was performed 
and the patient was given radiation with protons. Unlike con-
ventional photon radiotherapy, proton radiotherapy focuses 
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the maximum dose to the target tissue while sparing normal 
tissues from much of the entry dose and the entire exit dose. 
This occurs as protons lose only a small amount of their en-
ergy in tissue until they reach the target tissue, after which 
the residual energy is rapidly lost, resulting in a steep treat-
ment gradient [49]. Therefore, the use of proton-beam radia-
tion for craniospinal treatment may allow a partial sparing 
of vertebral body radiation exposure, lessening the impact 
on this major component of hematopoeisis and lessening the 
degree of myelotoxcity.
Author (year) (ref)
Age range 
at dx
n First line Chemotherapy Outcomes
Biegel (1990) [44] 6 mos - 12 mos 3
Cy, VP-16, Cis, Vcr/Cis, Cy, Vcr, Mtx, CCNU/
Vcr, BCNU, Proc, Hydroxy, Cis, Ara-C
DOD 3 - 5 mos
Agranovich (1992) [54] 33 mos 1 Cis, Doxo DOD 8 mos
Weinblatt (1992) [55] - 1 Vcr, Act-D, Doxo, IT Mtx, IT Ara-C, IT HC NED 5 + yrs
Hanna (1993) [56] 8 mos - 6 yrs 3
Vcr, VP-16, Cis, Cy, Vcr, nitrogen mustard, IT 
Mtx/Ifos, VP-16, Carbo
DOD 6 - 15 mos
Olson (1995) [47] 18 mos - 5 yrs 3
IRS III based (Vcr, Cis, Doxo, Cy, VP-16, 
Act-D, IT Mtx, IT Ara-C, IT HC)
NED 6 - 42 mos
Dang (2003) [57] 4 wks - 25 mos 3
Vcr, Cy, Act-D, Doxo, Vcr, VP-16, Cis, Cy, 
Doxo, Ifos, IT thio/VP-16, Cis
DOD 5 mos - 1 year
Izychka-Swieszewska 
(2003) [58]
5 mos
8-in-1 (Vcr, CCNU, Proc, Hydroxy, Cis, Ara-C, 
Cy, MP) 
DOD 8 mos
Wharton (2003) [59] 31 mos - 14 yrs 3
UKCCSG SIOP PNET (Vcr, VP-16, Carbo, 
Cy)/UKCCSG infant brain tumor protocol (Vcr, 
Carbo, Cy, Mtx, Cis)
DOD 11 mos
AWD at 1 year
NED 4 yrs
Zimmerman (2005) 
[60]
14 mos - 11 yrs  4
DFCI/IRS III modiﬁ  ed* (Vcr, Cis, Doxo, 
Dexraz, Cy, VP-16, Actino, Tmz, IT Mtx, IT 
Ara-C, IT HC)
NED 33 mos - 4 yrs
Chen (2006) [28]
24 mos - 11.2 
yrs
11
VIP (Vinb, Ifos, Cis), IT Mtx +/-, ACNU/ICE + 
CECAT (Cy, VP-16, Carbo, Thio)
DOD 7 - 24 mos
AWD 15 - 17 mos
NED 35 - 105 mos
Fidani (2009) [61]
16 mos - 8.6 
yrs
8
ICE + CECAT (Cy, VP-16, Carbo, Thio)/ICE/
ICE+TMZ
DOD 8 - 13 mos
AWD 5 - 38 mos
NED 101 - 105 mos
Gardner (2008) [62] 4 - 52 mos 13
HSI (Induction: Cis, VP-16, Cy, Vcr, Consolid: 
Carbo, Thio, VP-16, ASCR)/HS II (same as HS 
I plus Mtx in Induction)
DOD/DOC 0.5 - 11.5 
mos
NED 42 - 67 mos
Lassaletta (2009) [63] 8 mos
ACNS 0121 (Vcr, Cy, Carbo, VP-16) and IT 
depot Ara-C
DOD 2 mos
Biswas (2009) [64] 6 years GTR, CSRT, VAC (Vcr, Doxo, Cy) NED 24 mos
6 years STR, VAC DOD < 2 mos
5 years STR, CSRT, VAC AWD?
18 mos STR, ICE DOD < 2 mos
Chi (2009) [45] 4 mos - 8.4 yrs 18
GTR, CRT, modiﬁ  ed IRS-III (Vcr, Dactino, Cy, 
Cis, Doxo, Tmz, IT Mtx, Ara-C, HC)
DOD/DOC 1 - 24 
mos
AWD 17 - 34 mos
NED 18 - 40 mos
Ertan (2009) [65] 8 mos - 8 yrs 2 ICE DOD 4 - 5 mos
Wang (2009) [66] 16 - 42 mos Cis, Ifos, VP-16, IT ACNU/TMZ**
AWD 12 mos
NED 59 mos
Table 2. Chemotherapy Used for AT/RT in Children
Ara-C: cytarabine; AWD: alive with disease; Bx: biopsy; Carbo: carboplatin; Cis: cisplatin; CSRT: craniospinal radiation therapy; 
Cy: cyclophosphamide; DOC: dead of complications; DOD: dead of disease; EBRT: external beam radiation therapy; GTR: gross 
total resection; HC: hydrocortisione; Hydroxy: hydroxyurea; ICE: ifosphamide, carboplatin, etoposide; Ifos: ifosphamide; IT: intra-
thecal; Mtx: methotrexate; NED: no evidence of disease; Proc: procarbazine; STR: subtotal resection; Tmz: temozolomide; Vcr: 
vincristine; VP-16: etoposide. * One patient received this second-line. ** One patient only received second-line chemotherapy.
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Laboratory studies have focused on establishing an AT/
RT in vitro cell culture model on which preclinical studies 
can investigate both chemotherapeutic agents as well as 
targeted therapies [50-53]. Insulin-growth factor-1 recep-
tor (IGF-1R) inhibition has been shown to sensitize cells to 
both chemotherapy and radiation [53]. Using AT/RT cells 
cultured from CSF, Narendran noted growth inhibition with 
low concentrations of arsenic trioxide, Prima-1 (targets mu-
tant p53 proteins), oxaliplatin, cisplatin and rebeccamycin. 
Thalidomide, etoposide, cytarabine and paclitaxel had inter-
mediate MICs. The optimal treatment remains to be deﬁ  ned, 
but the increasing recognition of this disease and the devel-
opment of good laboratory models will hopefully accelerate 
therapeutic advances.
Conclusion
AT/RT remains a rare adult disease. However, as our knowl-
edge of AT/RTs increases we anticipate that there will be 
more standardization of treatment. Aggressive resection 
followed by multimodality treatment appears to yield more 
long-term survivors. In adults, although the use of RT does 
not convey the same devastating developmental arrest, there 
are still reasons to minimize the effects to normal tissues 
particularly bone marrow, supporting the use of proton ra-
diation, particularly since CSRT is a standard treatment. Al-
though the optimal chemotherapy regimen has not been de-
ﬁ  ned for adults with AT/RT, several regimens have been used 
with evidence of activity. Further advances in treatment will 
likely require more laboratory studies generating novel treat-
ment regimens for clinical trial testing. The rarity of adult 
AT/RT suggests that treatment regimens will continue to rely 
on advances in pediatric treatments.
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